Federal contractor · MORRISVILLE, NC

WE PHARMA, INC.

WE PHARMA, INC. received $873.6K in federal contract obligations in FY2026, on 2 awards (−10% vs FY2025). Since FY2018: $6.7M. Its largest customer was Food and Drug Administration ($873.6K).

Obligations · FY2026
$873.6K
New awards
2
Sole-source
0.0%
Single offer
0.0%
UEI
EWAMVJSFNK29
Other than small businessMinority-owned
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 211.9KFY2018
  2. 28.9KFY2019
  3. 677.7KFY2020
  4. 1MFY2021
  5. 746.8KFY2022
  6. 1.3MFY2023
  7. 834.9KFY2024
  8. 971.8KFY2025
  9. 873.6KFY2026

Top buying agencies

Obligations in FY2026.

  1. Food and Drug Administration$873.6K100%
    2 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

  1. Health & medical$873.6K100%

Where the work was performed

  1. Montgomery County, MD$873.6K100%

Integrity signals

Shares of the year's obligations, next to the country's.

  • Low competition0.0%
    US 39% · $0
  • Sole-source awards0.0%
    US 30% · $0
  • Single-offer competitions0.0%
    US 8.8% · $0
  • Urgency justifications0.0%
    US 5.1% · $0

A signal is a reason to look closer, not evidence of wrongdoing: most sole-source awards are lawful and justified.

Largest awards

  1. TO OBTAIN A RELIABLE SOURCE OF CURRENTLY MARKETED DRUG PRODUCTS FOR FDA RESEARCH STUDIES SUPPORTING THE GDUFA REGULATORY SCIENCE PROGRAM, WITHIN THE OFFICE OF PHARMACEUTICAL QUALITY RESEARCH (OPQR).$1.5M
    Food and Drug Administration· Montgomery County, MD· Health & medical· Jul 28, 2025 – May 21, 2026· 75F40125F19004
  2. PHARMACEUTICAL PRODUCTS FOR FDA/OPQ DOMESTIC MANUFACTURING AND REGULATORY PURPOSES.$213.6K
    Food and Drug Administration· Montgomery County, MD· Health & medical· Mar 23, 2023 – Jul 24, 2026· 75F40123F19003

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 2 markets (agency × industry), FY2024–FY2026.

  1. REPLIGEN CORPORATION$426.9K
    WALTHAM, MA · 2 entities · 6.5% of this company's obligations are in markets they both serveFood and Drug Administration · Pharmaceutical and medicine manufacturing
  2. RADIX BIOSOLUTIONS LLC$732.8K+122% in FY2026
    GEORGETOWN, TX · 6.5% of this company's obligations are in markets they both serveFood and Drug Administration · Pharmaceutical and medicine manufacturing
  3. IGGENIX, INC.$100K
    SOUTH SAN FRANCISCO, CA · 3.7% of this company's obligations are in markets they both serveFood and Drug Administration · Pharmaceutical and medicine manufacturing

Showing the top 3 of 15 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 3, 2026, loaded Oct 3, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 3, 2026, loaded Oct 3, 2026.